Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco IPO Will Value Company At $5.9-$6.5 Bil. – Amended Prospectus

Executive Summary

Merck's amended IPO prospectus for Medco Health Solutions suggests that the spin-off will be valued at just below the price that Merck paid for the business in 1993

You may also be interested in...



Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations

Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line

Philadelphia PBM investigation

The Philadelphia U.S. Attorney's Office has drafted a letter "presenting the government's position" on pharmacy benefit management activities, Medco discloses in most recent update to IPO prospectus. The company says it was "orally informed" that the letter was undergoing final reviews as of June 17. "Although we are unable to predict what its contents will be, the letter may address both the independent investigation commenced in 1998 and the allegations in the qui tam complaints," Medco says. "The government letter could seek payments and other remedies which could be material." Medco previously disclosed that it had received a formal notice from the Philadelphia Attorney indicating interest in pending "whistleblower" complaints against the company (1"The Pink Sheet" June 17, p. 14)...

Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations

Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line

Related Content

UsernamePublicRestriction

Register

PS040019

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel